Skip to main content
Top
Published in: Medical Oncology 4/2020

01-04-2020 | Hepatic Adenoma | Review Article

Current concepts in ablative procedures for primary benign liver lesions: a step forward to minimize the invasiveness of treatment when deemed necessary

Authors: Aldo Carnevale, Fabio Pellegrino, Alberto Cossu, Anna Maria Ierardi, Gian Carlo Parenti, Gianpaolo Carrafiello, Melchiore Giganti

Published in: Medical Oncology | Issue 4/2020

Login to get access

Abstract

With increased use of medical imaging, the incidental detection of benign solid liver tumors has become more frequent. Facing with benign disease, the indications for surgery are still object of discussion in light of the stable natural course of most lesions and obvious drawbacks of any surgical intervention; therefore, in most situations, a conservative approach is recommended, and surgery is mainly reserved for those cases with persistent or worsening symptoms, or who are at risk for complications as malignant transformation. The advent of ablative techniques has widened the range of treatment options available to these patients, presenting as a valid alternative to resection in terms of safety and efficacy in selected cases, particularly in patients who are considered poor surgical candidates and with smaller lesions. This review outlines the role of percutaneous ablative methods for benign solid liver tumors that are encountered in adults, providing a per histology analysis of the existing evidence. The up-to-date strategies for management of the most common benign solid tumors are recapitulated.
Literature
1.
go back to reference Belghiti J, Cauchy F, Paradis V, Vilgrain V. Diagnosis and management of solid benign liver lesions. Nat Rev Gastroenterol Hepatol. 2014;11:737–49.CrossRef Belghiti J, Cauchy F, Paradis V, Vilgrain V. Diagnosis and management of solid benign liver lesions. Nat Rev Gastroenterol Hepatol. 2014;11:737–49.CrossRef
2.
go back to reference Colombo M, Forner A, Ijzermans J, Paradis V, Reeves H, Vilgrain V, et al. EASL clinical practice guidelines on the management of benign liver tumours. J Hepatol. 2016;65:386–98.CrossRef Colombo M, Forner A, Ijzermans J, Paradis V, Reeves H, Vilgrain V, et al. EASL clinical practice guidelines on the management of benign liver tumours. J Hepatol. 2016;65:386–98.CrossRef
3.
go back to reference Kim Y, Amini N, He J, Margonis GA, Weiss M, Wolfgang CL, et al. National trends in the use of surgery for benign hepatic tumors in the United States. Surg Mosby Inc.; 2015;157:1055–64. Kim Y, Amini N, He J, Margonis GA, Weiss M, Wolfgang CL, et al. National trends in the use of surgery for benign hepatic tumors in the United States. Surg Mosby Inc.; 2015;157:1055–64.
4.
go back to reference Fodor M, Primavesi F, Braunwarth E, Cardini B, Resch T, Bale R, et al. Indications for liver surgery in benign tumours. Eur Surg—Acta Chir Austriaca. 2018;50:125–31. Fodor M, Primavesi F, Braunwarth E, Cardini B, Resch T, Bale R, et al. Indications for liver surgery in benign tumours. Eur Surg—Acta Chir Austriaca. 2018;50:125–31.
5.
go back to reference Grazioli L, Ambrosini R, Frittoli B, Grazioli M, Morone M. Primary benign liver lesions. Eur J Radiol Elsevier Ireland Ltd. 2017;95:378–98. Grazioli L, Ambrosini R, Frittoli B, Grazioli M, Morone M. Primary benign liver lesions. Eur J Radiol Elsevier Ireland Ltd. 2017;95:378–98.
6.
go back to reference Stoot JHMB, Coelen RJS, De Jong MC, Dejong CHC. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford). 2010;12:509–22.CrossRef Stoot JHMB, Coelen RJS, De Jong MC, Dejong CHC. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford). 2010;12:509–22.CrossRef
7.
go back to reference Seror O. Percutaneous hepatic ablation: what needs to be known in 2014. Diagn Interv Imaging. 2014;95:665–75.CrossRef Seror O. Percutaneous hepatic ablation: what needs to be known in 2014. Diagn Interv Imaging. 2014;95:665–75.CrossRef
8.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–41.CrossRef Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–41.CrossRef
9.
go back to reference Rhim H, Lim HK, Kim Y, Choi D. Percutaneous radiofrequency ablation of hepatocellular adenoma: Initial experience in 10 patients. J Gastroenterol Hepatol. 2008;23:e422–e427427.CrossRef Rhim H, Lim HK, Kim Y, Choi D. Percutaneous radiofrequency ablation of hepatocellular adenoma: Initial experience in 10 patients. J Gastroenterol Hepatol. 2008;23:e422–e427427.CrossRef
10.
go back to reference Van Vledder MG, Van Aalten SM, Terkivatan T, De Man RA, Leertouwer T, Ijzermans JNM. Safety and efficacy of radiofrequency ablation for hepatocellular adenoma. J Vasc Interv Radiol. 2011;22:787–93.CrossRef Van Vledder MG, Van Aalten SM, Terkivatan T, De Man RA, Leertouwer T, Ijzermans JNM. Safety and efficacy of radiofrequency ablation for hepatocellular adenoma. J Vasc Interv Radiol. 2011;22:787–93.CrossRef
11.
go back to reference Costa AF, Kajal D, Pereira A, Atri M. Should fat in the radiofrequency ablation zone of hepatocellular adenomas raise suspicion for residual tumour? Eur Radiol. 2017;27:1704–12.CrossRef Costa AF, Kajal D, Pereira A, Atri M. Should fat in the radiofrequency ablation zone of hepatocellular adenomas raise suspicion for residual tumour? Eur Radiol. 2017;27:1704–12.CrossRef
12.
go back to reference Mironov O, Jaberi A, Beecroft R, Kachura JR. Retrospective single-arm cohort study of patients with hepatocellular adenomas treated with percutaneous thermal ablation. Cardiovasc Intervent Radiol. 2018;41:935–41.CrossRef Mironov O, Jaberi A, Beecroft R, Kachura JR. Retrospective single-arm cohort study of patients with hepatocellular adenomas treated with percutaneous thermal ablation. Cardiovasc Intervent Radiol. 2018;41:935–41.CrossRef
13.
go back to reference Smolock AR, Cristescu MM, Potretzke TA, Ziemlewicz TJ, Lubner MG, Hinshaw JL, et al. Microwave ablation for the treatment of hepatic adenomas. J Vasc Interv Radiol. 2016;27:244–9.CrossRef Smolock AR, Cristescu MM, Potretzke TA, Ziemlewicz TJ, Lubner MG, Hinshaw JL, et al. Microwave ablation for the treatment of hepatic adenomas. J Vasc Interv Radiol. 2016;27:244–9.CrossRef
14.
go back to reference Cheng Z, Liang P, Yu X, Han Z, Liu F, Yu J, et al. Percutaneous microwave ablation for benign focal liver lesions: initial clinical results. Oncol Lett. 2017;13:429–34.CrossRef Cheng Z, Liang P, Yu X, Han Z, Liu F, Yu J, et al. Percutaneous microwave ablation for benign focal liver lesions: initial clinical results. Oncol Lett. 2017;13:429–34.CrossRef
15.
go back to reference Wang Z, Tang X, Qi X, Shi Y, Chi J, Li P, et al. Feasibility, safety, and efficacy of ultrasound-guided percutaneous microwave ablation for giant hepatic hemangioma. Int J Hyperth Taylor & Francis. 2018;35:246–52.CrossRef Wang Z, Tang X, Qi X, Shi Y, Chi J, Li P, et al. Feasibility, safety, and efficacy of ultrasound-guided percutaneous microwave ablation for giant hepatic hemangioma. Int J Hyperth Taylor & Francis. 2018;35:246–52.CrossRef
16.
go back to reference Liu F, Yu X, Liang P, Cheng Z, Han Z, Yu J. Ultrasonography-guided percutaneous microwave ablation for large hepatic cavernous haemangiomas. Int J Hyperth Informa UK Ltd. 2018;34:1061–6.CrossRef Liu F, Yu X, Liang P, Cheng Z, Han Z, Yu J. Ultrasonography-guided percutaneous microwave ablation for large hepatic cavernous haemangiomas. Int J Hyperth Informa UK Ltd. 2018;34:1061–6.CrossRef
17.
go back to reference Ziemlewicz TJ, Wells SA, Lubner MA, Musat AI, Hinshaw JL, Cohn AR, et al. Microwave ablation of giant hepatic cavernous hemangiomas. Cardiovasc Intervent Radiol. 2014;37:1299–305.CrossRef Ziemlewicz TJ, Wells SA, Lubner MA, Musat AI, Hinshaw JL, Cohn AR, et al. Microwave ablation of giant hepatic cavernous hemangiomas. Cardiovasc Intervent Radiol. 2014;37:1299–305.CrossRef
18.
go back to reference Ji J, Gao J, Zhao L, Tu J, Song J, Sun W. Computed tomography-guided radiofrequency ablation following transcatheter arterial embolization in treatment of large hepatic hemangiomas. Med (United States). 2016;95:1–5. Ji J, Gao J, Zhao L, Tu J, Song J, Sun W. Computed tomography-guided radiofrequency ablation following transcatheter arterial embolization in treatment of large hepatic hemangiomas. Med (United States). 2016;95:1–5.
19.
go back to reference Wang S, Yang M, Yang X, Xu L, Ke S, Ding X, et al. Endothelial pyroptosis underlies systemic inflammatory response following radiofrequency ablation of hepatic hemangiomas. Scand J Clin Lab Invest. 2019;79:619–28.CrossRef Wang S, Yang M, Yang X, Xu L, Ke S, Ding X, et al. Endothelial pyroptosis underlies systemic inflammatory response following radiofrequency ablation of hepatic hemangiomas. Scand J Clin Lab Invest. 2019;79:619–28.CrossRef
20.
go back to reference Gao J, Ding X, Ke S, Xin Z, Ning C, Sha Q, et al. Radiofrequency ablation in the treatment of large hepatic hemangiomas: a comparison of multitined and internally cooled electrodes. J Clin Gastroenterol. 2014;48:540–7.CrossRef Gao J, Ding X, Ke S, Xin Z, Ning C, Sha Q, et al. Radiofrequency ablation in the treatment of large hepatic hemangiomas: a comparison of multitined and internally cooled electrodes. J Clin Gastroenterol. 2014;48:540–7.CrossRef
21.
go back to reference Gao J, Ke S, Ding XM, Zhou YM, Qian XJ, Sun WB. Radiofrequency ablation for large hepatic hemangiomas: Initial experience and lessons. Surg (United States). 2013;153:78–85. Gao J, Ke S, Ding XM, Zhou YM, Qian XJ, Sun WB. Radiofrequency ablation for large hepatic hemangiomas: Initial experience and lessons. Surg (United States). 2013;153:78–85.
22.
go back to reference Gao J, Kong J, Ding XM, Ke S, Niu HG, Xin ZH, et al. Laparoscopic vs computerized tomography-guided radiofrequency ablation for large hepatic hemangiomas abutting the diaphragm. World J Gastroenterol. 2015;21:5941–9.CrossRef Gao J, Kong J, Ding XM, Ke S, Niu HG, Xin ZH, et al. Laparoscopic vs computerized tomography-guided radiofrequency ablation for large hepatic hemangiomas abutting the diaphragm. World J Gastroenterol. 2015;21:5941–9.CrossRef
23.
go back to reference Li X, An C, Liu F, Cheng Z, Han Z, Yu X, et al. The value of 3D visualization operative planning system in ultrasound-guided percutaneous microwave ablation for large hepatic hemangiomas: a clinical comparative study. BMC Cancer BMC Cancer. 2019;19:1–9.CrossRef Li X, An C, Liu F, Cheng Z, Han Z, Yu X, et al. The value of 3D visualization operative planning system in ultrasound-guided percutaneous microwave ablation for large hepatic hemangiomas: a clinical comparative study. BMC Cancer BMC Cancer. 2019;19:1–9.CrossRef
24.
go back to reference Li D, Yu J, Han Z, Cheng Z, Liu F, Dou J, et al. Risk factors of haemoglobinuria after microwave ablation of liver tumours. Clin Radiol. 2018;73:982.e9–982.e15.CrossRef Li D, Yu J, Han Z, Cheng Z, Liu F, Dou J, et al. Risk factors of haemoglobinuria after microwave ablation of liver tumours. Clin Radiol. 2018;73:982.e9–982.e15.CrossRef
25.
go back to reference Park SY, Tak WY, Jung MK, Jeon SW, Cho CM, Kweon YO, et al. Symptomatic-enlarging hepatic hemangiomas are effectively treated by percutaneous ultrasonography-guided radiofrequency ablation. J Hepatol. 2011;54:559–65.CrossRef Park SY, Tak WY, Jung MK, Jeon SW, Cho CM, Kweon YO, et al. Symptomatic-enlarging hepatic hemangiomas are effectively treated by percutaneous ultrasonography-guided radiofrequency ablation. J Hepatol. 2011;54:559–65.CrossRef
26.
go back to reference Tang X, Ding M, Lu B, Chi J, Wang T, Shi Y, et al. Outcomes of ultrasound-guided percutaneous microwave ablation versus surgical resection for symptomatic large hepatic hemangiomas. Int J Hyperthermia Taylor & Francis. 2019;36:632–9. Tang X, Ding M, Lu B, Chi J, Wang T, Shi Y, et al. Outcomes of ultrasound-guided percutaneous microwave ablation versus surgical resection for symptomatic large hepatic hemangiomas. Int J Hyperthermia Taylor & Francis. 2019;36:632–9.
27.
go back to reference Yang X, Lei C, Qiu Y, Shen S, Lu C, Yan L, et al. Selecting a suitable surgical treatment for hepatic angiomyolipoma: a retrospective analysis of 92 cases. ANZ J Surg. 2018;88:E664–E66969.CrossRef Yang X, Lei C, Qiu Y, Shen S, Lu C, Yan L, et al. Selecting a suitable surgical treatment for hepatic angiomyolipoma: a retrospective analysis of 92 cases. ANZ J Surg. 2018;88:E664–E66969.CrossRef
28.
go back to reference Pilati C, Letouzé E, Nault J-C, Imbeaud S, Boulai A, Calderaro J, et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell. 2014;25:428–41.CrossRef Pilati C, Letouzé E, Nault J-C, Imbeaud S, Boulai A, Calderaro J, et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell. 2014;25:428–41.CrossRef
29.
go back to reference Van Aalten SM, De Man RA, Ijzermans JNM, Terkivatan T. Systematic review of haemorrhage and rupture of hepatocellular adenomas. Br J Surg. 2012;99:911–6.CrossRef Van Aalten SM, De Man RA, Ijzermans JNM, Terkivatan T. Systematic review of haemorrhage and rupture of hepatocellular adenomas. Br J Surg. 2012;99:911–6.CrossRef
30.
go back to reference Agrawal S, Agarwal S, Arnason T, Saini S, Belghiti J. Management of hepatocellular adenoma: recent advances. Clin Gastroenterol Hepatol. 2015;13:1221–300.CrossRef Agrawal S, Agarwal S, Arnason T, Saini S, Belghiti J. Management of hepatocellular adenoma: recent advances. Clin Gastroenterol Hepatol. 2015;13:1221–300.CrossRef
31.
go back to reference Dokmak S, Cauchy F, Belghiti J. Resection, transplantation and local regional therapies for liver adenomas. Expert Rev Gastroenterol Hepatol. 2014;8:803–10.CrossRef Dokmak S, Cauchy F, Belghiti J. Resection, transplantation and local regional therapies for liver adenomas. Expert Rev Gastroenterol Hepatol. 2014;8:803–10.CrossRef
32.
go back to reference Dokmak S, Paradis V, Vilgrain V, Sauvanet A, Farges O, Valla D, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology. 2009;137:1698–705.CrossRef Dokmak S, Paradis V, Vilgrain V, Sauvanet A, Farges O, Valla D, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology. 2009;137:1698–705.CrossRef
33.
go back to reference van Aalten SM, Terkivatan T, de Man RA, van der Windt DJ, Kok NFM, Dwarkasing R, et al. Diagnosis and treatment of hepatocellular adenoma in the Netherlands: similarities and differences. Dig Surg. 2010;27:61–7.CrossRef van Aalten SM, Terkivatan T, de Man RA, van der Windt DJ, Kok NFM, Dwarkasing R, et al. Diagnosis and treatment of hepatocellular adenoma in the Netherlands: similarities and differences. Dig Surg. 2010;27:61–7.CrossRef
34.
35.
go back to reference Toro A, Mahfouz A-E, Ardiri A, Malaguarnera M, Malaguarnera G, Loria F, et al. What is changing in indications and treatment of hepatic hemangiomas: a review. Ann Hepatol. 2014;13:327–39.CrossRef Toro A, Mahfouz A-E, Ardiri A, Malaguarnera M, Malaguarnera G, Loria F, et al. What is changing in indications and treatment of hepatic hemangiomas: a review. Ann Hepatol. 2014;13:327–39.CrossRef
36.
go back to reference Trastek VF, van Heerden JA, Sheedy PF, Adson MA. Cavernous hemangiomas of the liver: resect or observe? Am J Surg. 1983;145:49–53.CrossRef Trastek VF, van Heerden JA, Sheedy PF, Adson MA. Cavernous hemangiomas of the liver: resect or observe? Am J Surg. 1983;145:49–53.CrossRef
37.
go back to reference Hall GW. Kasabach-Merritt syndrome: pathogenesis and management. Br. J. Haematol. 2001. 112:851–62. Hall GW. Kasabach-Merritt syndrome: pathogenesis and management. Br. J. Haematol. 2001. 112:851–62.
38.
go back to reference Miura JT, Amini A, Schmocker R, Nichols S, Sukato D, Winslow ER, et al. Surgical management of hepatic hemangiomas: a multi-institutional experience. HPB. 2014;16:924–8.CrossRef Miura JT, Amini A, Schmocker R, Nichols S, Sukato D, Winslow ER, et al. Surgical management of hepatic hemangiomas: a multi-institutional experience. HPB. 2014;16:924–8.CrossRef
39.
go back to reference Zhang W, Huang ZY, Ke CS, Wu C, Zhang ZW, Zhang BX, et al. Surgical Treatment of Giant Liver Hemangioma Larger Than 10cm: A Single Center’s Experience with 86 Patients. Med (United States). Lippincott Williams and Wilkins; 2015;94:e1420. Zhang W, Huang ZY, Ke CS, Wu C, Zhang ZW, Zhang BX, et al. Surgical Treatment of Giant Liver Hemangioma Larger Than 10cm: A Single Center’s Experience with 86 Patients. Med (United States). Lippincott Williams and Wilkins; 2015;94:e1420.
40.
go back to reference O’Rafferty C, O’Regan GM, Irvine AD, Smith OP. Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon. Br J Haematol. 2015;171:38–51.CrossRef O’Rafferty C, O’Regan GM, Irvine AD, Smith OP. Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon. Br J Haematol. 2015;171:38–51.CrossRef
41.
go back to reference Navarro AP, Gomez D, Lamb CM, Brooks A, Cameron IC. Focal nodular hyperplasia: a review of current indications for and outcomes of hepatic resection. HPB. 2014;16:503–11.CrossRef Navarro AP, Gomez D, Lamb CM, Brooks A, Cameron IC. Focal nodular hyperplasia: a review of current indications for and outcomes of hepatic resection. HPB. 2014;16:503–11.CrossRef
42.
go back to reference Zhou YM, Li B, Xu F, Wang B, Li DQ, Zhang XF, et al. Clinical features of hepatic angiomyolipoma. Hepatobiliary Pancreat Dis Int. 2008;7:284–7.PubMed Zhou YM, Li B, Xu F, Wang B, Li DQ, Zhang XF, et al. Clinical features of hepatic angiomyolipoma. Hepatobiliary Pancreat Dis Int. 2008;7:284–7.PubMed
Metadata
Title
Current concepts in ablative procedures for primary benign liver lesions: a step forward to minimize the invasiveness of treatment when deemed necessary
Authors
Aldo Carnevale
Fabio Pellegrino
Alberto Cossu
Anna Maria Ierardi
Gian Carlo Parenti
Gianpaolo Carrafiello
Melchiore Giganti
Publication date
01-04-2020
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2020
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-020-01355-z

Other articles of this Issue 4/2020

Medical Oncology 4/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.